AI주식인사이트AI Stock Insight
D

종근당바이오

063160KOSPI의약품 제조업

39.5 / 100

Reference Date: 2026-06-10

Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is undervalued vs. peers but ROE is below the industry average. Plunged 19.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

CKDBio is a fermentation and biotechnology specialist established in 2001, operating core businesses in API, probiotics, microbiome, and botulinum toxin. Leveraging over 50 years of technical expertise and adherence to global cGMP standards, the company supplies high-value products to over 40 countries. In the botulinum toxin sector, it has secured China NMPA Phase 3 clinical approval, actively expanding its global market presence.

Number of Employees

533people

Average Salary

69.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 11.934.0Point
PBR
0.67Industry Average 0.894.0Point

In line with industry avg

ROE
-2.24Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
16.37Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲0.2% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲43.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 15,590Won52-week high 24,50052-week low 15,590
1-month return0.0Point

1m -19.26% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral분기보고서 (2026.03)2026-05-15